Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume -, Issue -, Pages 204748732094198
Publisher
SAGE Publications
Online
2020-07-28
DOI
10.1177/2047487320941987
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diagnosis and Management of Statin Intolerance
- (2019) Rodrigo Alonso et al. Journal of Atherosclerosis and Thrombosis
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes
- (2019) Philippe Gabriel Steg et al. CIRCULATION
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
- (2018) Christie M. Ballantyne et al. ATHEROSCLEROSIS
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statin Intolerance
- (2017) Steven E. Nissen JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey
- (2016) Ž. Reiner et al. ATHEROSCLEROSIS
- Statin intolerance – a question of definition
- (2016) Engi Abdel-Hady Algharably et al. Expert Opinion On Drug Safety
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- (2015) Patrick M. Moriarty et al. Journal of Clinical Lipidology
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Association between non-adherence to statin and hospitalization for cardiovascular disease and all-cause mortality in a national cohort
- (2014) Sukyoun Shin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Resistance and intolerance to statins
- (2014) Ž. Reiner NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Statins in the primary prevention of cardiovascular disease
- (2013) Željko Reiner Nature Reviews Cardiology
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started